Thalidomide protects mice against LPS-induced shock
Autor(a) principal: | |
---|---|
Data de Publicação: | 1997 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Medical and Biological Research |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1997001000010 |
Resumo: | Thalidomide has been shown to selectively inhibit TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> production in vitro by lipopolysaccharide (LPS)-stimulated monocytes. TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> has been shown to play a pivotal role in the pathophysiology of endotoxic shock. Using a mouse model of LPS-induced shock, we investigated the effects of thalidomide on the production of TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> and other cytokines and on animal survival. After injection of 100-350 µg LPS into mice, cytokines including TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font>, IL-6, IL-10, IL-1ß, GM-CSF and IFN-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">g</font> were measured in the serum. Administration of 200 mg/kg thalidomide to mice before LPS challenge modified the profile of LPS-induced cytokine secretion. Serum TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> levels were reduced by 93%, in a dose-dependent manner, and TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> mRNA expression in the spleens of mice was reduced by 70%. Serum IL-6 levels were also inhibited by 50%. Thalidomide induced a two-fold increase in serum IL-10 levels. Thalidomide treatment did not interfere with the production of GM-CSF, IL-1ß or IFN-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">g</font>. The LD50 of LPS in this model was increased by thalidomide pre-treatment from 150 µg to 300 µg in 72 h. Thus, at otherwise lethal doses of LPS, thalidomide treatment was found to protect animals from death |
id |
ABDC-1_9b08a8c2b38bb278159864690dccd977 |
---|---|
oai_identifier_str |
oai:scielo:S0100-879X1997001000010 |
network_acronym_str |
ABDC-1 |
network_name_str |
Brazilian Journal of Medical and Biological Research |
repository_id_str |
|
spelling |
Thalidomide protects mice against LPS-induced shockendotoxic shockthalidomidecytokinesinflammationThalidomide has been shown to selectively inhibit TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> production in vitro by lipopolysaccharide (LPS)-stimulated monocytes. TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> has been shown to play a pivotal role in the pathophysiology of endotoxic shock. Using a mouse model of LPS-induced shock, we investigated the effects of thalidomide on the production of TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> and other cytokines and on animal survival. After injection of 100-350 µg LPS into mice, cytokines including TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font>, IL-6, IL-10, IL-1ß, GM-CSF and IFN-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">g</font> were measured in the serum. Administration of 200 mg/kg thalidomide to mice before LPS challenge modified the profile of LPS-induced cytokine secretion. Serum TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> levels were reduced by 93%, in a dose-dependent manner, and TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> mRNA expression in the spleens of mice was reduced by 70%. Serum IL-6 levels were also inhibited by 50%. Thalidomide induced a two-fold increase in serum IL-10 levels. Thalidomide treatment did not interfere with the production of GM-CSF, IL-1ß or IFN-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">g</font>. The LD50 of LPS in this model was increased by thalidomide pre-treatment from 150 µg to 300 µg in 72 h. Thus, at otherwise lethal doses of LPS, thalidomide treatment was found to protect animals from deathAssociação Brasileira de Divulgação Científica1997-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1997001000010Brazilian Journal of Medical and Biological Research v.30 n.10 1997reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/S0100-879X1997001000010info:eu-repo/semantics/openAccessMoreira,A.L.Wang,J.Sarno,E.N.Kaplan,G.eng1998-10-07T00:00:00Zoai:scielo:S0100-879X1997001000010Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:1998-10-07T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false |
dc.title.none.fl_str_mv |
Thalidomide protects mice against LPS-induced shock |
title |
Thalidomide protects mice against LPS-induced shock |
spellingShingle |
Thalidomide protects mice against LPS-induced shock Moreira,A.L. endotoxic shock thalidomide cytokines inflammation |
title_short |
Thalidomide protects mice against LPS-induced shock |
title_full |
Thalidomide protects mice against LPS-induced shock |
title_fullStr |
Thalidomide protects mice against LPS-induced shock |
title_full_unstemmed |
Thalidomide protects mice against LPS-induced shock |
title_sort |
Thalidomide protects mice against LPS-induced shock |
author |
Moreira,A.L. |
author_facet |
Moreira,A.L. Wang,J. Sarno,E.N. Kaplan,G. |
author_role |
author |
author2 |
Wang,J. Sarno,E.N. Kaplan,G. |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Moreira,A.L. Wang,J. Sarno,E.N. Kaplan,G. |
dc.subject.por.fl_str_mv |
endotoxic shock thalidomide cytokines inflammation |
topic |
endotoxic shock thalidomide cytokines inflammation |
description |
Thalidomide has been shown to selectively inhibit TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> production in vitro by lipopolysaccharide (LPS)-stimulated monocytes. TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> has been shown to play a pivotal role in the pathophysiology of endotoxic shock. Using a mouse model of LPS-induced shock, we investigated the effects of thalidomide on the production of TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> and other cytokines and on animal survival. After injection of 100-350 µg LPS into mice, cytokines including TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font>, IL-6, IL-10, IL-1ß, GM-CSF and IFN-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">g</font> were measured in the serum. Administration of 200 mg/kg thalidomide to mice before LPS challenge modified the profile of LPS-induced cytokine secretion. Serum TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> levels were reduced by 93%, in a dose-dependent manner, and TNF-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">a</font> mRNA expression in the spleens of mice was reduced by 70%. Serum IL-6 levels were also inhibited by 50%. Thalidomide induced a two-fold increase in serum IL-10 levels. Thalidomide treatment did not interfere with the production of GM-CSF, IL-1ß or IFN-<!-- $MVD$:face("Symbol") --><FONT FACE="Symbol">g</font>. The LD50 of LPS in this model was increased by thalidomide pre-treatment from 150 µg to 300 µg in 72 h. Thus, at otherwise lethal doses of LPS, thalidomide treatment was found to protect animals from death |
publishDate |
1997 |
dc.date.none.fl_str_mv |
1997-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1997001000010 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1997001000010 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0100-879X1997001000010 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
dc.source.none.fl_str_mv |
Brazilian Journal of Medical and Biological Research v.30 n.10 1997 reponame:Brazilian Journal of Medical and Biological Research instname:Associação Brasileira de Divulgação Científica (ABDC) instacron:ABDC |
instname_str |
Associação Brasileira de Divulgação Científica (ABDC) |
instacron_str |
ABDC |
institution |
ABDC |
reponame_str |
Brazilian Journal of Medical and Biological Research |
collection |
Brazilian Journal of Medical and Biological Research |
repository.name.fl_str_mv |
Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC) |
repository.mail.fl_str_mv |
bjournal@terra.com.br||bjournal@terra.com.br |
_version_ |
1754302928833740800 |